OA11850A - Immunomodulatory steroids, in particular the hemihydrate of 16, alpha-bromoepiandrosterone. - Google Patents

Immunomodulatory steroids, in particular the hemihydrate of 16, alpha-bromoepiandrosterone. Download PDF

Info

Publication number
OA11850A
OA11850A OA1200100237A OA1200100237A OA11850A OA 11850 A OA11850 A OA 11850A OA 1200100237 A OA1200100237 A OA 1200100237A OA 1200100237 A OA1200100237 A OA 1200100237A OA 11850 A OA11850 A OA 11850A
Authority
OA
OAPI
Prior art keywords
chr10
infection
group
use according
compound
Prior art date
Application number
OA1200100237A
Other languages
English (en)
Inventor
Clarence Nathaniel Ahlem
Luis Daniel Dos Anjos Carvalho
James Martin Frincke
William Heggie
Patrick T Frendergast
Christopher L Reading
Krupakar Paul Thadikonda
Russell Neil Vernon
Original Assignee
Hollis Eden Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals filed Critical Hollis Eden Pharmaceuticals
Publication of OA11850A publication Critical patent/OA11850A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003Androstane derivatives
    • C07J1/0011Androstane derivatives substituted in position 17 by a keto group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
OA1200100237A 1999-03-23 2000-03-23 Immunomodulatory steroids, in particular the hemihydrate of 16, alpha-bromoepiandrosterone. OA11850A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12605699P 1999-03-23 1999-03-23
US14002899P 1999-06-16 1999-06-16
US41490599A 1999-10-08 1999-10-08
US16404899P 1999-11-08 1999-11-08

Publications (1)

Publication Number Publication Date
OA11850A true OA11850A (en) 2006-03-06

Family

ID=27494614

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100237A OA11850A (en) 1999-03-23 2000-03-23 Immunomodulatory steroids, in particular the hemihydrate of 16, alpha-bromoepiandrosterone.

Country Status (22)

Country Link
EP (1) EP1163256B1 (cs)
JP (1) JP2002540119A (cs)
KR (2) KR100717897B1 (cs)
CN (1) CN1243767C (cs)
AP (1) AP2001002285A0 (cs)
AT (1) ATE259825T1 (cs)
AU (1) AU781997B2 (cs)
BR (1) BR0009476A (cs)
CA (1) CA2365081A1 (cs)
CZ (1) CZ20013420A3 (cs)
DE (1) DE60008353T2 (cs)
DK (1) DK1163256T3 (cs)
ES (1) ES2215631T3 (cs)
HK (1) HK1046002B (cs)
HU (1) HUP0203429A3 (cs)
IL (1) IL144916A0 (cs)
NO (2) NO320801B1 (cs)
NZ (1) NZ513803A (cs)
OA (1) OA11850A (cs)
PT (1) PT1163256E (cs)
RU (2) RU2295534C2 (cs)
WO (1) WO2000056757A1 (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129282A1 (en) 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
DK1955700T3 (da) 1999-09-30 2011-05-23 Harbor Biosciences Inc Terapeutisk behandling af androgenreceptor-betingede lidelser
AU2001241779A1 (en) 2000-02-25 2001-09-03 Hollis-Eden Pharmaceuticals, Inc. Method of treatment of prostate cancer
WO2002069977A1 (en) * 2001-03-01 2002-09-12 Hollis-Eden Pharmaceuticals, Inc. Use of certain steroids for treatment of blood cell deficiencies
FR2829697B1 (fr) * 2001-09-14 2004-03-19 Mayoly Spindler Lab Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin
KR20050057086A (ko) 2002-08-28 2005-06-16 홀리스-에덴 파마슈티칼즈, 인코포레이티드 치료적 처치 방법
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
KR101293350B1 (ko) * 2003-12-26 2013-08-05 다이쇼 세이야꾸 가부시끼가이샤 호중구증다 억제제
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
CN104072564B (zh) * 2013-03-28 2016-08-17 广州市赛普特医药科技股份有限公司 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途
CN106565654B (zh) * 2016-10-14 2018-08-31 云南中烟工业有限责任公司 一种从白云参中提取的新型黄酮类化合物、其制备方法及其用途
US10836788B2 (en) 2019-02-05 2020-11-17 SD Chem, Inc. Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof
CN114907333B (zh) * 2022-05-11 2023-07-04 中国人民解放军军事科学院军事医学研究院 环丙甲酰胺衍生物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH197784A (de) * 1934-05-25 1938-05-15 Schering Kahlbaum Ag Verfahren zu Darstellung von D5,6-trans-Androstendiol-3,17.
IE72193B1 (en) * 1983-08-02 1997-03-26 Res Corp Technologies Inc Steroids useful as anti-cancer anti-obesity anti-hyperglycemic anti-autoimmune and anti-hypercholesterolemic agents
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
JPH0289327A (ja) * 1988-09-27 1990-03-29 Matsushita Electron Corp 銀ペースト塗布装置
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
IE60458B1 (en) * 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates

Also Published As

Publication number Publication date
RU2001128881A (ru) 2003-09-27
NO20056167L (no) 2001-11-21
RU2006133273A (ru) 2008-03-27
CZ20013420A3 (cs) 2002-04-17
ES2215631T3 (es) 2004-10-16
CN1243767C (zh) 2006-03-01
RU2417792C2 (ru) 2011-05-10
WO2000056757A1 (en) 2000-09-28
EP1163256B1 (en) 2004-02-18
KR20020003217A (ko) 2002-01-10
HK1046002B (zh) 2006-10-20
CN1355809A (zh) 2002-06-26
BR0009476A (pt) 2002-02-19
DK1163256T3 (da) 2004-06-28
JP2002540119A (ja) 2002-11-26
HK1046002A1 (en) 2002-12-20
NO20014588D0 (no) 2001-09-21
HUP0203429A3 (en) 2004-07-28
DE60008353D1 (de) 2004-03-25
AU781997B2 (en) 2005-06-23
PT1163256E (pt) 2004-07-30
IL144916A0 (en) 2002-06-30
NO20014588L (no) 2001-11-21
NZ513803A (en) 2004-06-25
RU2295534C2 (ru) 2007-03-20
AU3919000A (en) 2000-10-09
KR20070007394A (ko) 2007-01-15
AP2001002285A0 (en) 2001-12-31
CA2365081A1 (en) 2000-09-28
EP1163256A1 (en) 2001-12-19
ATE259825T1 (de) 2004-03-15
KR100717897B1 (ko) 2007-05-14
HUP0203429A2 (hu) 2003-01-28
NO320801B1 (no) 2006-01-30
DE60008353T2 (de) 2005-09-08

Similar Documents

Publication Publication Date Title
US6667299B1 (en) Pharmaceutical compositions and treatment methods
US8022234B2 (en) Compounds and compositions
US7947846B2 (en) 15-OXA-steroid compounds
US20030060425A1 (en) Immune modulation method using steroid compounds
US8541600B2 (en) 11-aza, 11-thia and 11-oxa sterol compounds and compositions
US20030083231A1 (en) Blood cell deficiency treatment method
EP1372664A1 (en) Use of certain steroids for treatment of blood cell deficiencies
AU2002244247A1 (en) Use of certain steroids for treatment of blood cell deficiencies
AU781997B2 (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
EP1422234A2 (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
AU2005211675B2 (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
ZA200106980B (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.[bromoepiandrosterone.
MXPA01009624A (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone